Preview

Медицинская иммунология

Расширенный поиск

ЭНДОКАННАБИНОИДЫ И ЭЙКОЗАНОИДЫ: БИОСИНТЕЗ, МЕХАНИЗМЫ ИХ ВЗАИМОСВЯЗИ, РОЛЬ В ИММУННЫХ ПРОЦЕССАХ

https://doi.org/10.15789/1563-0625-2013-2-119-130

Полный текст:

Аннотация

Обзор посвящен современным представлениям о метаболитах арахидоновой кислоты –
эндоканнабиноидам и эйкозаноидам, путях их биосинтеза, механизмах взаимодействия и роли в иммунных процессах. Приводятся новые данные литературы и результаты собственных исследований
о перекрестности ферментативных путей биосинтеза эндоканнабиноидов и эйкозаноидов; влиянии
синтетических лигандов каннабиноидных рецепторов на активность продукции провоспалительных
цитокинов, эйкозаноидов; взаимосвязи между реактивностью иммунной системы и  уровнем экспрессии эндоканнабиноидных рецепторов.

Об авторах

Ю. К. Караман
Владивостокский филиал ФГБУ «Дальневосточный научный центр физиологии и патологии дыхания» СО РАМН – НИИ медицинской климатологии и восстановительного лечения, г. Владивосток
Россия
к.б.н., cтарший научный сотрудник лаборатории биомедицинских исследований


Е. Г. Лобанова
Владивостокский филиал ФГБУ «Дальневосточный научный центр физиологии и патологии дыхания» СО РАМН – НИИ медицинской климатологии и восстановительного лечения, г. Владивосток
Россия
к.м.н., cтарший научный сотрудник лаборатории биомедицинских исследований


Список литературы

1. Крылатов А.В., Ужаченко Р.В., Маслов Л.Н., Угдыжекова Д.С. Анандамид и R-(+)метанандамид предупреждают развитие ишемических и реперфузионных аритмий у крыс посредством стимуляции СВ2-рецепторов // Экспериментальная и клиническая фармакология. – 2002. – № 3. – С. 6-9. Krylatov A.V., Uzhachenko R.V., Maslov L.N., Ugdyzhekova D.S. Anandamid i R-[+]metanandamid preduprezhdayut razvitie ishemicheskikh i reperfuzionnykh aritmiy u krys posredstvom stimulyatsii CB2-retseptorov bloood leukocytes from healthy people and patiens with allergy]. Immunopatologiya, allergologiya, infektologiya – Immunopathology, Allergology, Infectology, 2003, no. 2, pp. 86-91.

2. Лобанова [Исаченко] Е.Г., Виткина Т.И., Бердышев Е.В. Влияние лигандов каннабиноидных ре- цепторов WIN 55,212-2 и анандамида на выработку TNF-α и ИЛ-8 лейкоцитами крови здоровых лиц и больных с аллергопатологией // Иммунопатология, аллергология, инфектология. – 2003. – № 2. – С. 86-91. Lobanova [Isachenko] E.G., Vitkina T.I., Berdyshev E.V. Vliyanie ligandov kannabinoidnykh retseptorov WIN 55,212-2 i anandamida na vyrabotku TNF-α i IL-8 leykotsitami krovi zdorovykh lits i bol`nykh s allergopatologiey [Iuflunce of cannabionoid receptor ligands and anandamide on TNF-α and IL-8 production by peripheral bloood leukocytes from healthy people and patiens with allergy]. Immunopatologiya, allergologiya, infektologiya – Immunopathology, Allergology, Infectology, 2003, no. 2, pp. 86-91.

3. Лобанова Е.Г. Влияние лигандов каннабиноидных рецепторов на реактивность иммунокомпетентных клеток. – Изд. Lambert Academic Publishing (Германия). – 2011. – 128 с. Lobanova E.G. Vliyanie ligandov kannabinoidnykh retseptorov na reaktivnost` immunokompetentnykh kletok [Influence of cannabioid receptor ligands on immunocompetent cells activity]. Publishing, German, Izdatel`stvo Lambert Academic – Izdatelstvo Lambert Academic, 2011. 128 p.

4. Лобанова Е.Г. Влияние синтетических лигандов каннабиноидных рецепторов на экспрессию эйкозаноидов in vitro // Бюллетень СО РАМН. – 2012. – Т. 32, № 2. – С. 5-8. Lobanova E.G. Vliyanie sinteticheskikh ligandov kannabinoidnykh retseptorov na ekspressiyu eykozanoidov in vitro [Influence of the cannabinoid receptors synthetic ligands on eicosanoids synthesis in vitro]. Byulleten` SO RAMN – Bulletin of the Siberian Branch of the Russian Academy of Medical Sciences, 2012, no. 2, pp. 5-8.

5. Лобанова Е.Г. Действие синтетических лигандов каннабиноидных рецепторов на реактивность иммунокомпетентных клеток in vitro // Медицинская иммунология. – 2009. – Т. 11, № 2-3. – С. 261-264. Lobanova E.G. Deystvie sinteticheskikh ligandov kannabinoidnykh retseptorov na reaktivnost` immunokompetentnykh kletok in vitro [Effects of syntetic cannabinoid receptor ligands win 55,212-2 and anandamid upon in vitro activity of immunocompetent cells]. Meditsinskaya immunologiya – Medical Immunology, 2009, vol. 11, no. 2-3, pp. 261-264.

6. Лобанова Е.Г. Роль эндоканнабиноидных рецепторов в регуляции иммунного ответа // Медицинская иммунология. – 2012. – Т. 14, № 3. – С. 189-194. Lobanova E.G. Rol` endokannabinoidnykh retseptorov v regulyatsii immunnogo otveta [Role of endocannabinoid receptors in immune response regulation]. Meditsinskaya immunologiya – Medical Immunology, 2012, vol. 14, no. 3, pp. 189-194.

7. Сергеева М.Г., Варфоломеева А.Т. Каскад арахидоновой кислоты. – М.: Народное образование, 2006. – 256 с. Sergeeva M.G., Varfolomeeva A.T. Kaskad arakhidonovoy kisloty [Cascade of arachidonic acid]. Moscow, «Narodnoe Obrazovanie» – «Narodnoe Obrazovanie», 2006. 256 p.

8. Чурюканов М.В., Чурюканов В.В. Функциональная организация и терапевтический потенциал эндогенной каннабиноидной системы // Экспериментальная и клиническая фармакология. – 2004. – № 67 (2). – С. 70-78. Churyukanov M.V., Churyukanov V.V. Funktsional`naya organizatsiya i terapevticheskiy potentsial endogennoy kannabinoidnoy sistemy [Functional organization ant therapeutic potential of the endogenous cannabinoid system]. Eksperimental`naya i klinicheskaya farmakologiya – Experimental and Clinical Pharmacology, 2004, vol. 67, no. 2, pp. 70-78.

9. Baker D., Pryce G., Croxford J. L., Brown P., Pertwee R.G., Huffman J.W., Layward L. Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature, 2000, no. 404, pp. 84-87.

10. Battista N., Tommaso M., Bari M., Maccarrone M. The endocannabinoid system: an overview. Front. Behav. Neurosci, 2012, no. 6, p. 9.

11. Berdyshev E.V., Boichot E., Germain N., Allain N., Anger J.P., Lagente V. Influence of fatty acid ethanolamides and D9-tetrahydrocannabinol on cytokine and arachidonate release by mononuclear cells. Eur. J. Pharmacol., 1997, no. 330, pp. 231-240.

12. Bergstr m S., Danielsson H., Samuelsson B. Enzymatic formation of prostaglandin E2 from arachidonic acid. Biochim. Biophys. Acta, 1964, no. 90, рр. 207-210.

13. Brash A.R. Arachidonic acid as a bioactive molecule. J. Clin. Invest., 2001, vol. 107, pp. 1339-1345.

14. Brenowitz S.D., Regehr W.G. Calcium dependence of retrograde inhibition by endocannabinoids at synapses in to purkinje cells. J. Neurosci, 2003, vol. 23, pp. 6373-6384.

15. Bueb J.L., Lambert D.M., Tschirhart E.J. Receptor-independent effects of natural cannabinoids in rat peritoneal mast cells in vitro. Biochim. Biophys. Acta, 2001, vol. 1538, pp. 252-259.

16. Cadas H., Gaillet S., Beltramo M., Venance L., Piomelli D. Biosynthesis of an endogenous cannabinoidprecursor in neurons and its control by calcium and cAMP. J. Pancreas, 2004, no. 5, pp. 41-43.

17. Cravatt B.F., Demarest K., Patricelli M.P., Bracey M.H., Giang D.K., Martin B.R., Lichtman A.H. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc. Natl. Acad. Sci. USA, 2001, vol. 98, no. 16, pp. 9371-9376.

18. Devane W.A., Dysarz F.A.I., Johnson M.R., Melvin L.S., Howlett A.C. Determination and characterization of a cannabinoid receptor in rat brain. Mol. Pharmacol., 1988, vol. 34, pp. 605-613.

19. Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., Gibson D., Mandelbaum A., Etinger A., Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science, 1992, vol. 258, pp. 1946-1949.

20. Di Marzo V. Endocannabinoids: synthesis and degradation. Rev. Physiol. Biochem. Pharmacol., 2008, vol. 160, no. 1, pp. 1289-1296.

21. Diaz S., Specter S., Volanderhoek J.Y., Coffey R.G. The effect of delta-9-tetrahydrocannabinol on arachidonic acid metabolism in human peripheral blood mononuclear cells. J. Pharmacol. Exp. Ther., 1994, vol. 268, pp. 1289-1296.

22. Dixon R.A. Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis. Nature, 1990, vol. 343, pp. 282-284.

23. Farquhar-Smith W.P., Jaggar S.I., Rice A.S. Attenuation of nerve growth factor-induced visceral hyperalgesia via cannabinoid CB1 and CB2-like receptors. Pain, 2002, vol. 97, pp. 11-21.

24. Farquhar-Smith W.P., Rice A.S. Administration of endocannabinoids prevents a referred hyperalgesia associated with inflammation of the urinary bladder. Anesthesiology, 2001, vol. 94, pp. 507-513.

25. Fonseca R.F., Arco D.I., Bermudez-Silva F.J. The endocannabinoid system: physiology and pharmacology. Alcohol, 2005, vol. 40, no. 1, pp. 2-14.

26. Forsell P.K., Brunnstr m A., Johannesson M., Claesson H.E. Metabolism of anandamide into eoxamides by 15-Lipoxygenase-1 and glutathione transferases. Lipids, 2012 Jun 9 [Epub ahead of print]. [Anandamide and R-[+]-methanandamide prevent development of ischemic and reperfusion arrhythmia in rats by stimulation of CB2-receptors]. Eksperimental`naya i klinicheskaya farmakologiya – Experimental and Clinical Pharmacology, 2002, no. 3, pp. 6-9.

27. Funk C.D. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science, 2001, vol. 294, рр. 1871- 1875.

28. Galiegue S., Mary S., Marchand J., Dussossoy D., Carri re D., Carayon P., Bouaboula M., Shire D., Le Fur G., Casellas P. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur. J. Biochem., 1995, no. 232, pp. 54-61.

29. Gaoni Y., Mechoulam R. Isolation, structure and partial synthesis of an active constiuent of hashish. J. Am. Chem. Soc., 1964, no. 86, pp. 1646-1647.

30. Gertsch J., Leonti M., Raduner S., Racz I., Chen J.Z., Xie X.Q., Altmann K.H., Karsak M., Zimmer A. Beta-caryophyllene is a dietary cannabinoid. PNAS, 2008, vol. 105, no. 26, pp. 9099-9104.

31. Gilroy D.W. Eicosanoids and the endogenous control of acute inflammatory resolution. Int. J. Biochem. Cell Biol., 2010, no. 42, no. 4, pp. 524-528.

32. Giuffrida A., Beltramo M., Piomelli D. Mechanisms of Endocannabinoid Inactivation: Biochemistry and Pharmacology. J. Pharmacol. Exp. Ther., 2001, no. 298, pp. 7-14.

33. Goldyne M.E., Burrish G.F., Poubelle P., Borgeat P. Arachidonic acid metabolism among human mononuclear leukocytes. Lipoxygenas-related pathways. J. Biol. Chem., 1984, no. 259, pp. 8815-8819.

34. Habayeb О.M., Taylor A.H., Bell S.C., Taylor D.J., Konje J.C. Expression of the endocannabinoid system in human first trimester placenta and its role in trophoblast proliferation. Endocrinology. 2008, no. 149, no. 10, pp. 5052-5060.

35. Hampson A.J., Hill W.A., Zan-Phillips M., Makriyannis A., Leung E., Eglen R.M., Bornheim L.M. Anandamide hydroxylation by brain lipoxygenase:metabolite structures and potencies at the cannabinoid receptor. Biochim. Biophys. Acta, 1995, no. 16, pp. 173-179.

36. Hiley C.R. Endocannabinoids and the heart. J. Cardiovolasc. Pharmacol., 2009, vol. 53, no. 4, pp. 267-276.

37. Howlett A.C., Wilken G.H., Pigg J.J., Houston D.B., Lan R., Liu Q., Makriyannis A. Azido- and isothiocyanato-substituted aryl pyrazoles bind covalently to he CB1 cannabinoid receptor and impair signal transduction. J. Neurochem., 2000, vol. 74, pp. 2174-2181.

38. Katona S., Kaminski E., Sanders ., Zajicek J. Cannabinoid influence on cytokine profile in multiple sclerosis. Clin. Exp. Immunol., 2005, vol. 140, no. 3, pp. 580-585.

39. Kearn C.S., Hillard C.J. International cannabinoid research society. Simposium on the Cannabinoids. Burlington, 1999. 44 р.

40. Klein T.W., Newton C., Friedman H. Cannabinoid receptors and the cytokine network. Adv. Exp. Med. Biol., 1998, no. 437, pp. 215-222.

41. Kozak K.R., Crews B.C., Ray J.L., Tai H.H., Morrow J.D., Marnett L.J. Metabolism of prostaglandin glycerol esters and prostaglandin ethanolamides in vitro and in vivo. J. of Biological. Chemistry, 2001, no. 276, pp. 993-998.

42. Kulkarni-Narla A., Brown D.R. Localization of CB1-cannabinoid receptor immunoreactivity in the porcine enteric nervous system. Cell Tissue Res., 2000, vol. 302, no. 1, pp. 73-80.

43. Lewis R.A., Austen K.F., Soberman R.J. Leukotrienes and other products of the 5-lipoxygenase pathway. Biochemistry and relation to pathobiology in human diseases. N. Engl. J. Med., 1990, vol. 323, pp. 645-655.

44. M rquez L., Abanades S., Andreu M. Endocannabinoid system and bowel inflammation. Med. Clin. (Barc), 2008, vol. 131, no. 13, pp. 513-517.

45. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature, 1990, vol. 346, pp. 561-564.

46. Mechoulam R., Fride E., Di Marzo V. Endocannabinoids. Eur. J. Pharmacol., 1998, vol. 359, pp. 1-18.

47. Melis M., Pistis M., Perra S., Muntoni A.L., Pillolla G., Gessa G.L. Endocannabinoids mediate presynaptic inhibition of glutamatergic transmission in rat ventral tegmental area dopamine neurons through activation of CB1 receptors. J. Neurosci, 2004, vol. 24, pp. 3-62.

48. Murakami M. Regulation of prostaglandin E2 biosynthesis by inducible membrane-associated prostaglandin E2 synthase that acts in concert with cyclooxygenase-2. J. Biol. Chem., 2000, vol. 275, pp. 783-792.

49. Narumiya S., Fitzgerald G.A. Genetic and pharmacological analysis of prostanoid receptor function. J. Clin. Invest., 2001, vol. 108, pp. 25-30.

50. Pertwee R.G., Brown D.T. Cannabis: The genus Cannabis. Amsterdam: Harwood Academic Publishers, 1998, pp. 125-174.

51. Pertwee R.G., Ross R.A. Cannabinoid receptors and their ligands. Prostaglandins, Leukotrienes and Essential Fatty Acids, 2002, vol. 66, no. 2-3, pp. 101-121.

52. Pertwee R.G. Pharmacological actions of cannabinoids. In: Cannabinoids. Handbook of Experimental Pharmacology, 2005, vol. 168, pp. 1-51.

53. Racz I., G thert M., Zimmer A. Anandamide effects on 5-HT3 receptors in vivo. Eur. J. Pharmacol., 2008, vol. 596, pp. 98-101.

54. Robson P. Therapeutic aspects of cannabis and cannabinoids. Br. J. Psychiatry, 2001, vol. 178, pp. 107-115.

55. Rodriguez F., Arco I.D., Bermudez-Silva F.J. The endocannabinoid system: physiology and pharmacology. Alcohol, 2005, vol. 40, pp. 2-14.

56. Rouzer C.A., Marnett L.J. Endocannabinoid Oxygenation by Cyclooxygenases, Lipoxygenases, and Cytochromes P450: Cross-Talk between the Eicosanoid and Endocannabinoid Signaling Pathways. Chem. Rev., 2011, vol. 111, no. 10, pp. 5899-5921.

57. Samuelsson B., Goldyne M., Granstr m E., Hamberg M., Hammarstrom S., Malmsten C. Prostaglandins and thromboxanes. Annu. Rev. Biochem., 1978, vol. 47, рр. 997-1029.

58. Smith M.L., Murphy R.C. The eicosanoids: cyclooxygenase, lipoxygenase and epoxygenase pathways. Biochemistry of lipids, lipoproteins and membranes. Amsterdam: Elsevier, 2002. 300 р.

59. Smith W.L., Garavito R.M., DeWitt D.L. Prostaglandin endoperoxide H synthases [cyclooxygenases]-1 and -2. J. Biol. Chem., 1996, vol. 271, pp. 157-160.

60. Snider N.T., Kornilov A.M., Kent U.M., Hollenberg P.F. Anandamide Metabolism by Human Liver and Kidney Microsomal Cytochrome P450 Enzymes to Form Hydroxyeicosatetraenoic and Epoxyeicosatrienoic Acid Ethanolamides. J. Pharmacol. Exp. Ther., 2007, vol. 321, рр. 590-597.

61. Soberman R.J., Christmas P. The organization and consequences of eicosanoid signaling. Clin. Invest., 2003, vol. 111, no. 8, pp. 1107-1113.

62. Spector A.A. Arachidonic acid cytochrome P450 epoxygenase pathway. J. Lipid Res., 2009, vol. 50, pp. 59-65.

63. Sugiura T., Kondo S., Sukagawa A., Nakane S., Shinoda A., Itoh K., Yamashita A., Waku K. 2-Arachidonoylgylcerol: A Possible Endogenous Cannabinoid Receptor Ligand in Brain. Biochem. Biophys. Res. Commun., 1995, vol. 215, рр. 89-97.

64. Tapiero H., Nguyen B., Couvreur G. Polyunsaturated fatty acids [PUFA] and eicosanoids in human health and pathologies. Biomed. Pharmacother., 2002, vol. 56, pp. 215-222.

65. Van Dorp D.A., Beerthuis R.K., Nugeteren D.H., Vonkeman H. The biosynthesis of prostaglandins. Biophys. Acta, 1964, vol. 90, pp. 204-207.

66. Wang J., Natsuo U. Biology of endocannabinoid synthesis system. Prostaglandins & Other Lipid Mediators, 2009, vol. 89, no. 3-4, pp. 112-119.

67. Yu M., Ives D., Ramesha C.S. Synthesis of Prostaglandin E2 Ethanolamide from Anandamide by Cyclooxygenase-2. J. Biol. Chem., 1997, vol. 272, pp. 21181-21186.


Для цитирования:


Караман Ю.К., Лобанова Е.Г. ЭНДОКАННАБИНОИДЫ И ЭЙКОЗАНОИДЫ: БИОСИНТЕЗ, МЕХАНИЗМЫ ИХ ВЗАИМОСВЯЗИ, РОЛЬ В ИММУННЫХ ПРОЦЕССАХ. Медицинская иммунология. 2013;15(2):119-130. https://doi.org/10.15789/1563-0625-2013-2-119-130

For citation:


Karaman Y.K., Lobanova E.G. ENDOCANNABINOIDS AND EICOSAMOIDS: BIOSYNTHESIS AND INTERACTIONS WITH IMMUNE RESPONSE. Medical Immunology (Russia). 2013;15(2):119-130. (In Russ.) https://doi.org/10.15789/1563-0625-2013-2-119-130

Просмотров: 578


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1563-0625 (Print)
ISSN 2313-741X (Online)